Welcome to our dedicated page for Celanese Del SEC filings (Ticker: CE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Celanese’s (CE) latest 10-K can feel like walking through a refinery—dense process charts, commodity pricing models, and pages of environmental risk factors. If you have searched for Celanese insider trading Form 4 transactions or the Celanese quarterly earnings report 10-Q filing, you already know the struggle. Traditional document viewers bury acetic acid cost swings, engineered materials revenue, and sustainability liabilities deep inside footnotes.
Stock Titan ends that complexity. Our AI parses every disclosure the moment it hits EDGAR, turning raw text into clear commentary. From Celanese Form 4 insider transactions real-time alerts that spotlight executive stock moves to a comparative Celanese earnings report filing analysis that shows quarter-over-quarter margin shifts, we surface what matters. Ask any device for understanding Celanese SEC documents with AI and receive a Celanese annual report 10-K simplified summary in seconds—risk factors, segment data, and cash-flow drivers translated into plain language.
Because Celanese’s value hinges on volatile methanol feedstock, joint-venture output, and specialty polymer demand, context is critical. Our coverage explains every 8-K update, with Celanese 8-K material events explained in straightforward terms, and drills into the DEF 14A so Celanese proxy statement executive compensation details are upfront. Whether you need Celanese executive stock transactions Form 4 before a pricing announcement or real-time alerts on plant outages, Stock Titan’s AI-guided workspace delivers complete SEC filings explained simply—updated continuously and ready for decisive action.
Amendment No. 13 to Schedule 13G discloses that First Trust Portfolios L.P., First Trust Advisors L.P. and The Charger Corporation jointly own 8,507,784 shares of FT Vest Nasdaq-100® Buffer ETF � December (CUSIP 33740F649) as of 30 Jun 2025.
The holding equals 45.74 % of the ETF’s outstanding shares. Voting and dispositive power are shared among the reporting persons; none has sole authority. Shares are held through unit investment trusts and other investment vehicles sponsored or advised by the filers, and vote-casting is generally executed by the trusts� trustee to mirror external shareholder decisions. Each filer disclaims ultimate beneficial ownership.
Filers are classified as: BD (First Trust Portfolios), IA (First Trust Advisors) and HC (The Charger Corporation). The certification states the stake was acquired in the ordinary course and not to influence control of the issuer.
Milestone Pharmaceuticals Inc. (MIST) � Form 4 insider transaction
On 11 July 2025, President, CEO and Director Joseph Oliveto purchased 66,666 issuer Units at $1.50 per Unit. Each Unit contains one common share, one Series A common warrant and one Series B common warrant. Consequently:
- Common shares acquired: 66,666 (A-coded). Mr. Oliveto now directly owns 347,221 common shares.
- Series A warrants: 66,666 warrants, exercise price $1.50, fully vested, expire 11 July 2026.
- Series B warrants: 66,666 warrants, exercise price $1.875, fully vested, expire 11 July 2030.
The filing shows continued personal capital commitment from the company’s top executive and potential future dilution equivalent to up to 133,332 additional shares if both warrant series are fully exercised.
FAQ
What is the current stock price of Celanese Del (CE)?
What is the market cap of Celanese Del (CE)?
What are the primary products of Celanese Corp Del?
Which industries does Celanese serve?
How does Celanese generate its revenue?
What makes Celanese's chemical solutions unique?
How does Celanese maintain its competitive edge?
What role does research and development play at Celanese?
How is Celanese positioned in the global market?
How does Celanese collaborate with its customers?
